Article
Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.
Nature cancer - 1 Jun 2026
Ghannam Jack Y, Bryan Julian, Weiss Jakob, Kovarsky Daniel, Merrell David, Messer Conor, Schlueter-Kuck Kristy, Fell Geoffrey G, Lim-Fat Mary Jane, Youssef Gilbert, Rahman Rifaquat, Qin Lei, Young Geoffrey S, Janes J Thomas, Van Orden McKayla, Pfaff Kathleen L, Gans Andrew, Lin Emma S, Huang Raymond Y, Danysh Brian P, Parida Laxmi, Li Shuqiang, Wen Patrick Y, Chiocca E Antonio, Neuberg Donna, Ligon Keith L, Tirosh Itay, Reardon David A, Getz Gad, Wu Catherine J
Abstract excerpt
The determinants of immune checkpoint blockade (ICB) response in glioblastoma (GBM) with wild-type isocitrate dehydrogenase remain poorly understood. Here we profiled 181 ICB-treated GBM cases using bulk DNA sequencing, bulk RNA sequencing and single-nucleus RNA sequencing to investigate the genomic features associated with ICB outcomes. Baseline tumor transcriptional subtype was predictive of overall survival...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
